BioPorto Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Los beneficios de BioPorto han disminuido a una tasa media anual de -0.03%, mientras que en la industria Biotechs los beneficios crecieron en un 7.7% anualmente. Los ingresos han ido creciendo a una tasa media de 6.7% al año.

Información clave

-0.03%

Tasa de crecimiento de los beneficios

18.8%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	18.7%
Tasa de crecimiento de los ingresos	6.7%
Rentabilidad financiera	-70.8%
Margen neto	-175.6%
Última actualización de beneficios	30 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Oct 16

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

May 28

BioPorto A/S' (CPH:BIOPOR) Path To Profitability

Mar 01

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

Jan 24

A Look At BioPorto's (CPH:BIOPOR) CEO Remuneration

Dec 20

The BioPorto A/S (CPH:BIOPOR) Analysts Have Been Trimming Their Sales Forecasts

Nov 23

BioPorto A/S (CPH:BIOPOR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Nov 21

Desglose de ingresos y gastos

Cómo gana y gasta dinero BioPorto. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

CPSE:BIOPOR Ingresos, gastos y beneficios (DKK Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Sep 24	35	-61	61	27
31 Mar 24	32	-54	51	26
31 Dec 23	31	-56	55	25
30 Sep 23	33	-70	62	28
30 Jun 23	30	-78	63	32
31 Mar 23	31	-75	65	33
31 Dec 22	29	-76	63	35
30 Sep 22	27	-68	58	36
30 Jun 22	27	-62	56	33
31 Mar 22	25	-59	51	30
31 Dec 21	24	-57	50	30
30 Sep 21	25	-54	48	27
30 Jun 21	24	-60	48	29
31 Mar 21	25	-62	48	31
31 Dec 20	23	-62	49	28
30 Sep 20	22	-64	45	30
30 Jun 20	24	-68	54	29
31 Mar 20	25	-69	59	25
31 Dec 19	27	-70	62	25
30 Sep 19	29	-61	63	22
30 Jun 19	28	-51	55	16
31 Mar 19	27	-43	47	17
31 Dec 18	26	-38	41	19
30 Sep 18	24	-38	37	22
30 Jun 18	25	-36	34	25
31 Mar 18	24	-35	33	24
31 Dec 17	25	-32	33	22
30 Sep 17	25	-29	57	25
30 Jun 17	23	-27	49	18
31 Mar 17	21	-26	40	14
31 Dec 16	21	-23	31	10
30 Sep 16	20	-21	18	10
30 Jun 16	20	-16	18	10
31 Mar 16	21	-12	18	10
31 Dec 15	20	-11	18	10
30 Sep 15	20	-11	20	9
30 Jun 15	19	-12	20	9
31 Mar 15	18	-13	20	9
31 Dec 14	19	-13	20	9
30 Sep 14	18	-15	19	10
30 Jun 14	19	-19	19	10
31 Mar 14	18	-20	19	10
31 Dec 13	17	-22	19	10

Ingresos de calidad: BIOPOR actualmente no es rentable.

Margen de beneficios creciente: BIOPOR actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: BIOPOR no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 0.03% al año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de BIOPOR en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: BIOPOR no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-18.2%).

Rentabilidad financiera

Alta ROE: BIOPOR tiene una rentabilidad financiera negativa (-70.83%), ya que actualmente no es rentable.

BioPorto Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023)

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

BioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Recent updates

New minor risk - Market cap size

Bioporto A/S Maintains Revenue Guidance for the Year 2024

BioPorto A/S Initiates Patient Enrollment for US Study of ProNephro AKI (NGAL) for Adult Use at Massachusetts General Hospital

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

Consensus EPS estimates fall by 80%

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bioporto A/S Affirms Earnings Guidance for 2024

New major risk - Share price stability

New minor risk - Shareholder dilution

BioPorto A/S Appoints Niels Høy Nielsen as Member of the Executive Management Team, Effective August 1, 2024

Bioporto A/S Provides Revenue Guidance for 2024

First quarter 2024 earnings released: kr.0.04 loss per share (vs kr.0.048 loss in 1Q 2023)

Bioporto A/S Appoints Gry Louise Husby Larsen as Chief Legal Officer and Member of the Executive Management Team, Effective as of April 15, 2024

Bioporto A/S Announces Tonni Bülow-Nielsennot to Stand for Election

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

BioPorto A/S Announces CEO Changes

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

BioPorto A/S to Report Nine Months, 2024 Results on Oct 30, 2024

BioPorto A/S, Annual General Meeting, Apr 30, 2024

New major risk - Share price stability

BioPorto A/S Receives FDA 510(k) Clearance for NGAL Test in the United States

BioPorto A/S Announces Resignation of Jan Leth Christensen as Board Member

Consensus estimates of losses per share improve by 16%

New major risk - Financial position

Bioporto A/S Provides Revenue Guidance for the Fiscal Year 2023

Bioporto A/S Announces Resignation of Neil Goldman as CFO

BioPorto A/S announced that it has received $0.11 million in funding

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

BioPorto A/S Maintains Earnings Guidance for the Year 2023

We Think BioPorto (CPH:BIOPOR) Needs To Drive Business Growth Carefully

New minor risk - Shareholder dilution

High number of new and inexperienced directors

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

BioPorto A/S Maintains Financial Guidance for 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Hopeful That BioPorto (CPH:BIOPOR) Will Use Its Cash Wisely

BioPorto A/S, Annual General Meeting, Apr 27, 2023

BioPorto A/S Appoints Nis Kruse as EVP of Strategic Partnerships and Gm of EMEA & Apac

Less than half of directors are independent

BioPorto A/S Submits Application for Marketing Authorization of NGAL Test to the US Food and Drug Administration

BioPorto A/S Revises Earnings Guidance for the Year 2022

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

BioPorto A/S Revises Earnings Guidance for the Year 2022

Second quarter 2022 earnings: Revenues exceed analyst expectations

BioPorto A/S Revises Earnings Guidance for the Year 2022

BioPorto A/S Achieves Targeted Enrollment in Clinical Study Supporting FDA De Novo Submission for The NGAL Test in the U.S

BioPorto A/S Appoints Dr. Prasad Devarajan as New Senior Medical Director

We're Keeping An Eye On BioPorto's (CPH:BIOPOR) Cash Burn Rate

BioPorto A/S Maintains its Earnings Guidance for the Year 2022

Price target decreased to kr.3.50

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

BioPorto A/S Provides Earnings Guidance for the Full Year 2022

Is BioPorto (CPH:BIOPOR) In A Good Position To Deliver On Growth Plans?

Consensus forecasts updated

Third quarter 2021 earnings released: kr.0.04 loss per share (vs kr.0.087 loss in 3Q 2020)

Here's Why We're Not Too Worried About BioPorto's (CPH:BIOPOR) Cash Burn Situation

Second quarter 2021 earnings released: kr.0.051 loss per share (vs kr.0.077 loss in 2Q 2020)

BioPorto A/S Maintains Earnings Guidance for the Year 2021

BioPorto A/S Provides Pipeline Update Regarding COVID-19 Test

Companies Like BioPorto (CPH:BIOPOR) Are In A Position To Invest In Growth

First quarter 2021 earnings released: kr.0.06 loss per share (vs kr.0.088 loss in 1Q 2020)

BioPorto A/S Provides Earning Guidance for the Year 2021

Independent Vice Chairman Torben Nielsen has left the company

Independent Director has left the company

Price target decreased to kr.6.00

Consensus revenue estimates fall to kr.30.0m

Full year 2020 earnings released: kr.0.30 loss per share (vs kr.0.41 loss in FY 2019)